Abstract: Objective To evaluate the clinical efficacy and safety of Shenkang injection combined with calcium dobesilate in the treatment of chronic kidney disease. Methods We searched PubMed，Wanfang，and CNKI databases to collect clinical research results on evaluating the efficacy and safety of Shenkang injection combined with calcium dobesilate in the treatment of chronic kidney disease. The search time period was from the establishment of the database to December 25，2019. The RevMan5.3 software was used for meta-analysis. Results A total of 7 randomized controlled trials （RCTs） were included，including 653 patients. The results of the meta-analysis showed that compared with calcium dobesilate group，Scr decreased［MD = -31. 45，95%CI（-50. 23，-12. 66），P = 0. 001］，BUN decreased［MD = -3. 52，95%CI（-5. 24，-1. 79），P < 0. 000 01］，UA decreased［MD = -79. 72，95%CI（-100. 75，-58. 69），P < 0. 000 01］，CysC decreased［MD = -1. 04，95%CI（-1. 34，-0. 73），P < 0. 000 01］，Ccr increased［MD = 9. 81，95%CI（7. 13，12. 50），P < 0. 000 01］，and total effective rate increased［OR = 4. 56，95%CI（2. 24，9. 30），P < 0. 000 1］in Shenkang injection combined with calcium dobesilate group；and the incidence of adverse reactions between the two groups was not statistically significant［OR = 0. 66，95%CI（0. 27，1. 63），P = 0. 37］. Conclusion The efficacy of Shenkang injection combined with calcium dobesilate in the treatment of chronic kidney disease is better than that of calcium dobesilate alone. The safety of the two groups is equivalent.

Key words: chronic kidney disease, Shenkang injection, calcium dobesilate, Meta-analysis